Related Experiment Video
Updated: Feb 4, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Nivolumab induces impressive responses in relapsed/refractory classic Hodgkin lymphoma: Single institutional
Reyad Dada1,2, Yazeed Zabani3
11 King Faisal Specialist Hospital and Research Centre, Jeddah, Kingdom of Saudi Arabia.
Objectives:
Cancer can escape the immune system through different mechanisms. One such mechanism is the expression of program death ligand-1 which binds to PD-1 receptor on activated T cells, subsequently leading to inhibition of the immune response against cancer cells. Nivolumab is a novel antibody that binds to PD-1 and prevents such immune tolerance. Two recently published controlled clinical trials confirmed the clinical efficacy of single-agent nivolumab in pretreated patients with classical Hodgkin lymphoma.
Patients And Methods:
We treated 10 heavily pretreated patients with classical Hodgkin lymphoma with the new novel PD-1 inhibitor nivolumab. We report on the outcome and safety of this agent in these patients.
Results:
After four cycles, the response rate was 80%. Seven of 10 gained complete metabolic remission. No serious adverse events were observed. The available literature is being reviewed.
Conclusions:
Pretreated classical Hodgkin lymphoma is amenable to novel immunotherapy. Nivolumab induces clinically meaningful responses with excellent tolerability. The drug enriches our treatment options by reviving the response of the immune system against cancer. Further controlled studies are needed to determine the effectiveness on a large patient cohort.
Insights
Nivolumab, a PD-1 inhibitor, shows high response rates and excellent tolerability in heavily pretreated classical Hodgkin lymphoma patients. This immunotherapy revives the immune system against cancer, offering a promising new treatment option.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Cancer immune evasion mechanisms include Program Death Ligand-1 (PD-L1) expression, which inhibits T-cell responses.
- PD-1 receptor interaction with PD-L1 leads to immune tolerance, allowing cancer cells to escape immune surveillance.
- Nivolumab is a novel antibody designed to block the PD-1 pathway, thereby preventing immune suppression.
Purpose of the Study:
- To evaluate the efficacy and safety of nivolumab in heavily pretreated patients with classical Hodgkin lymphoma.
- To assess the response rate and tolerability of PD-1 inhibition in this patient population.
Main Methods:
- A cohort of 10 heavily pretreated classical Hodgkin lymphoma patients received nivolumab.
- Treatment involved four cycles of the PD-1 inhibitor.
- Patient outcomes and adverse events were closely monitored and reported.
Main Results:
- An overall response rate of 80% was observed after four cycles of nivolumab.
- Seven out of 10 patients achieved complete metabolic remission.
- No serious adverse events were reported during the study, indicating good tolerability.
Conclusions:
- Classical Hodgkin lymphoma, even in pretreated patients, is responsive to novel immunotherapy with nivolumab.
- Nivolumab demonstrates clinically significant efficacy and excellent tolerability, expanding treatment options.
- Further large-scale controlled studies are warranted to confirm these findings in a broader patient population.
Related Concept Videos
First Impression
Classical Conditioning
Ivan Pavlov observed that dogs...
Managing Impressions
Impression Management Techniques IV: Altercasting
Principles of Classical Conditioning
During the...
Classical Conditioning in Daily Life
John B. Watson and Rosalie Rayner famously demonstrated the development of fear through classical conditioning in their experiment with Little Albert. They paired the...

